Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
Portfolio Pulse from
Immuron Limited has entered into an exclusive distribution agreement to launch ProIBS® for treating IBS symptoms in Australia and New Zealand. This expands their product portfolio, which includes the Travelan® brand.
March 05, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immuron Limited has signed an exclusive distribution agreement to launch ProIBS® in Australia and New Zealand, expanding its product offerings in the digestive health sector.
The launch of ProIBS® in new markets could enhance Immuron's revenue streams and strengthen its position in the digestive health sector. This positive development is likely to boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100